ACD/Labs, an informatics company that develops and commercializes software in support of digitalised R&D, has announced the release of a new two-part white paper series, AI-Digital-Physical Convergence: The Future of DMTA in Drug Discovery and Development. The series explores how pharmaceutical organisations can accelerate innovation by modernizing the design-make-test-analyse (DMTA) cycle through AI applications and scientific software working in concert with scientists and the physical experiments they undertake.
The papers describe the transformative potential of an “AI-digital-physical DMTA cycle”— which can help organisations reduce data preparation time for predictive modelling and AI/ML applications from 80% to zero.
Part one focuses on drug discovery and outlines how digital twins and AI can accelerate lead optimisation, reduce the burden of manual synthesis design, and improve decision-making across exploratory and confirmatory experimentation. By unifying design, synthesis, testing, and analysis, researchers can shorten the path to identifying viable clinical candidates while maintaining scientific rigour.
Part two discusses the implementation of these principles in pharmaceutical development focusing on chemistry, manufacturing, and controls (CMC). Innovations that accelerate pharmaceutical development can significantly reduce the cost of developing an API into a drug product. AI-augmented DMTA cycles enable organisations to implement quality by design (QbD) principles more effectively; leverage design of experiments (DoE) and Bayesian optimisation for iterative and robust design; apply process digital twins for continuous optimisation and regulatory readiness; and improve drug substance characterisation and drug product formulation with higher reproducibility and compliance.
The white paper series is now available for download at acdlabs.com/FutureofDMTA.
